Drupal.behaviors.print = function(context) {window.print();window.close();}>
Santaris Nears End of Phase II Trial of miRNA HCV Rx, Seeks Partnership Since GSK Opted Out
September 15, 2011
Santaris Nears End of Phase II Trial of miRNA HCV Rx, Seeks Partnership Since GSK Opted Out
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
UNC Teams Uncovers How HCV Uses miR-122 to Survive
January 5, 2012 / Gene Silencing News
EPO to Hear Mirrx Request for Resumption of Patent Proceedings Covering miRNA Rx Technology
January 20, 2011 / Gene Silencing News
Santaris Sues Mirrx Founder Over Blockmir Technology
May 6, 2010 / Gene Silencing News
Santaris Pharma to Begin Phase II Development of miRNA-Targeting HCV Drug
September 23, 2010 / Gene Silencing News
Regulus, GSK Ink Second miRNA Rx Collaboration
February 25, 2010 / Gene Silencing News